SiBone (SIBN) to Release Quarterly Earnings on Monday

SiBone (NASDAQ:SIBN) is anticipated to issue its Q3 2025 results after the market closes on Monday, November 10th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $46.6720 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Monday, November 10, 2025 at 4:30 PM ET.

SiBone Trading Up 3.8%

Shares of SIBN opened at $15.77 on Friday. SiBone has a fifty-two week low of $11.70 and a fifty-two week high of $20.05. The firm has a market cap of $680.32 million, a price-to-earnings ratio of -28.16 and a beta of 0.81. The firm has a 50 day moving average price of $15.23 and a 200-day moving average price of $16.51. The company has a debt-to-equity ratio of 0.21, a quick ratio of 7.00 and a current ratio of 8.38.

Insider Transactions at SiBone

In other news, SVP Michael A. Pisetsky sold 3,329 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $15.64, for a total value of $52,065.56. Following the transaction, the senior vice president directly owned 258,352 shares in the company, valued at $4,040,625.28. This trade represents a 1.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Anshul Maheshwari sold 3,461 shares of SiBone stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $15.57, for a total transaction of $53,887.77. Following the transaction, the chief financial officer directly owned 214,445 shares in the company, valued at $3,338,908.65. This represents a 1.59% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 32,009 shares of company stock valued at $485,884 over the last 90 days. 4.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On SiBone

A number of large investors have recently made changes to their positions in the company. State of Wyoming purchased a new stake in SiBone in the second quarter worth about $55,000. Canada Pension Plan Investment Board purchased a new position in shares of SiBone in the 2nd quarter valued at approximately $68,000. Tower Research Capital LLC TRC grew its holdings in shares of SiBone by 198.8% during the second quarter. Tower Research Capital LLC TRC now owns 4,897 shares of the company’s stock valued at $92,000 after buying an additional 3,258 shares during the last quarter. State of Tennessee Department of Treasury acquired a new position in shares of SiBone in the second quarter valued at about $137,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in SiBone during the 1st quarter worth approximately $225,000. 98.11% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on SIBN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of SiBone in a report on Wednesday, October 8th. Truist Financial reduced their price target on SiBone from $22.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, October 15th. Cantor Fitzgerald set a $25.00 target price on shares of SiBone and gave the company an “overweight” rating in a report on Monday, August 11th. Finally, Wall Street Zen downgraded shares of SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.00.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.